» Articles » PMID: 12406909

Induction of C/EBPalpha Activity Alters Gene Expression and Differentiation of Human CD34+ Cells

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2002 Oct 31
PMID 12406909
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

The CCAAT/enhancer binding protein alpha (C/EBPalpha) belongs to a family of transcription factors that are involved in the differentiation process of numerous tissues, including the liver and hematopoietic cells. C/EBPalpha(-/-) mice show a block in hematopoietic differentiation, with an accumulation of myeloblasts and an absence of mature granulocytes, whereas expression of C/EBPalpha in leukemia cell lines leads to granulocytic differentiation. Recently, dominant-negative mutations in the C/EBPalpha gene and down-regulation of C/EBPalpha by AML1-ETO, an AML associated fusion protein, have been identified in acute myelogenous leukemia (AML). To better understand the role of C/EBPalpha in the lineage commitment and differentiation of hematopoietic progenitors, we transduced primary human CD34(+) cells with a retroviral construct that expresses the C/EBPalpha cDNA fused in-frame with the estrogen receptor ligand-binding domain. Induction of C/EBPalpha function in primary human CD34(+) cells, by the addition of beta-estradiol, leads to granulocytic differentiation and inhibits erythrocyte differentiation. Using Affymetrix (Santa Clara, CA) oligonucleotide arrays we have identified C/EBPalpha target genes in primary human hematopoietic cells, including granulocyte-specific genes that are involved in hematopoietic differentiation and inhibitor of differentiation 1 (Id1), a transcriptional repressor known to interfere with erythrocyte differentiation. Given the known differences in murine and human promoter regulatory sequences, this inducible system allows the identification of transcription factor target genes in a physiologic, human hematopoietic progenitor cell background.

Citing Articles

CEBPA mutations in acute myeloid leukemia: implications in risk stratification and treatment.

Tien F, Hou H Int J Hematol. 2024; 120(5):541-547.

PMID: 38671183 DOI: 10.1007/s12185-024-03773-5.


New progress in the study of germline susceptibility genes of myeloid neoplasms.

Bi L, Ma T, Li X, Wei L, Liu Z, Feng B Oncol Lett. 2021; 21(4):317.

PMID: 33692849 PMC: 7933751. DOI: 10.3892/ol.2021.12578.


Bisphenols and Leydig Cell Development and Function.

Li X, Wen Z, Wang Y, Mo J, Zhong Y, Ge R Front Endocrinol (Lausanne). 2020; 11:447.

PMID: 32849262 PMC: 7411000. DOI: 10.3389/fendo.2020.00447.


Integrated nuclear proteomics and transcriptomics identifies S100A4 as a therapeutic target in acute myeloid leukemia.

Alanazi B, Munje C, Rastogi N, Williamson A, Taylor S, Hole P Leukemia. 2019; 34(2):427-440.

PMID: 31611628 PMC: 6995695. DOI: 10.1038/s41375-019-0596-4.


Intracellular calprotectin (S100A8/A9) controls epithelial differentiation and caspase-mediated cleavage of EGFR in head and neck squamous cell carcinoma.

Argyris P, Slama Z, Malz C, Koutlas I, Pakzad B, Patel K Oral Oncol. 2019; 95:1-10.

PMID: 31345374 PMC: 6662626. DOI: 10.1016/j.oraloncology.2019.05.027.